Morgan Stanley lowered the firm’s price target on Bayer (BAYRY) to EUR 26 from EUR 30 and keeps an Equal Weight rating on the shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BAYRY:
- BridgeBio price target raised to $49 from $48 at Scotiabank
- M&A News: Novartis Seals $3.1B Deal to Acquire Anthos
- Bayer sees new drugs boosting return to growth in 2027, WSJ reports
- Bayer: Gadoquatrane met primary, secondary endpoints in Phase III QUANTI studies
- BridgeBio receives positive CHMP opinion for acoramidis for ATTR-CM treatment